Inhaled RJ026 study for interstitial lung disease patients
Part of Lungs & breathing clinical trials.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have been diagnosed or are suspected to have interstitial lung disease (ILD) based on a chest CT scan
- Your lung function tests show FVC and DLCO are at least 40% of normal, and your FEV1/FVC ratio is 0.7 or higher
- You are able to undergo a bronchoscopy (a procedure to look inside your airways)
- You can use an inhaler correctly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called ICF004 in healthy adults to see if it is safe and how the body processes it. It may help in developing a new treatment for lung conditions.
This trial tests an investigational drug called NCR101 to see if it is safe and helps people with interstitial lung disease (a group of conditions that cause lung scarring and breathing problems). It may be an option if your lung disease has been stable and you are already on certain treatments.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This study tests a new inhaled powder (RC010) to see if it is safe and how the body processes it. It is for healthy adults who do not smoke and have no major health problems.
This trial is for adults with interstitial lung disease (a group of lung conditions that cause scarring). It aims to understand the disease better and may help find new ways to treat it.
This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.